Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Hall; Iris H.
Address:
Chapel Hill, NC
No. of patents:
26
Patents:












Patent Number Title Of Patent Date Issued
RE32868 Antihyperlipidemic compositions February 14, 1989
The invention concerns cyclic imides, diones, reduced diones and analogs thereof which are useful as antihyperlipidemic agents to reduce serum cholesterol and trigylcerides.
5455233 Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates October 3, 1995
Disclosed are oligonucleoside boranophosphates, or salts thereof, comprising a chain of natural or modified ribonucleotides or deoxyribonucleotides, containing at least one boronated internucleotide phospodiester linkage of the formula: ##STR1## W is selected from the group consi
5192761 1,2,4-triazolidine-3,5-diones and 1,3,5-triazine-2,4(1-H,3H)-diones, pharmaceutical compositions March 9, 1993
The invention provides pharmaceutical compositions comprising hypolipidemically active derivatives of 1,2,4-triazolidine-3,5-diones, 1,3,5-triazabicyclo[3.1.0]hexane-2,4-diones, and 1,3,5-triazine-2,4(1H,3H)-diones in a pharmaceutically acceptable carrier for treating hyperlipidemia
5177198 Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates January 5, 1993
A process of making oligoribonucleoside and deoxyribonucleoside boranophosphates and salts thereof is disclosed. The process comprises the steps of condensing a ribonucleotide or deoxyribonucleotide with a nucleoside phosphitylating agent, wherein the phosphitylating agent includes a
5143907 Phosphite-borane compounds, and method of making and using the same September 1, 1992
Phosphite-borane compounds of the formula ##STR1## wherein: each R.sub.1 is independently selected from: H; C.sub.1 -C.sub.10 alkyl; alkylaryl; aralkyl; aryl; monovalent metal ions; nucleosides; and quaternary ammonium ions, (R.sub.4).sub.4 N.sup.+, in which the substituents R.su
5130302 Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for usi July 14, 1992
A novel class of pharmaceutically active boronated nucleosides are provided. The nucleosides are boronated at a ring nitrogen of the purine or pyrimidine or analogues thereof. Also provided are phosphate esters of these nucleosides and oligomers thereof. Methods of making and using the
5034528 Compositions for the control of hyperlipidemia July 23, 1991
The invention provides pharmaceutical compositions comprising hypolipidemically active derivatives of 1,2,4-triazolidine-3,5-diones, 1,3,5-triazabicyclo[3.1.0]hexane-2,4-diones, and 1,3,5-triazine-2,4(1H,3H)-diones in a pharmaceutically acceptable carrier for treating hyperlipidemia
4999366 Isoxazolidine-3,5-diones, pharmaceutical compositions and method of treatment March 12, 1991
A method of controlling hyperlipidemia in mammals which comprises adminstering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different pr
4977268 Boron dipeptide compounds December 11, 1990
Novel boron dipeptide analogs and their corresponding amide derivatives which exhibit significant antihyperlipidemic and antineoplastic activities. Methods for preparing the boron containing compounds are disclosed as well as methods for utilizing the compounds to induce antihyperlip
4946963 Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones August 7, 1990
An isoxazolidin-3,5-dione for the control of hyperlipidemia in mammals having the following structural formula: ##STR1## wherein R.sup.1 and R.sup.2 are each an alkyl of 1 to 4 carbons; R.sup.3 is an alkoxybenzoyl group containing from 1 to 3 alkoxy groups wherein the alkoxy grou
4866058 Method for control of hyperlipidemia September 12, 1989
The present invention is directed to a method of controlling hyperlipidemia in mammals which comprises administering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: ##STR1## wherein R.sup.1 is hydro
4863967 N,N-diaminophthalamides September 5, 1989
A compound having the structural formula ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are hydrogen, C.sub.1 -C.sub.6 alkyl, halogen or C.sub.1 -C.sub.4 alkoxy is disclosed. These compounds demonstrate utility as hypolipidemic agents.The present invention is also
4861778 2,3-dihydrophthalazine-1,4-diones August 29, 1989
A compound having the structural formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the sam
4855493 Pharmacological active amine-carboxyboranes August 8, 1989
Amine-carboxyboranes (boron analogues of amino acids) which demonstrate sificant antitumor and antihyperlipidemic (cholesterol and /or triglyceride lowering) activities are disclosed.
4845130 Antihyperlipidemic amines July 4, 1989
Long chain alkyl amines are useful as anti-hyperlipidemic agents for lowering serum cholesterol and triglyceride levels in mammals. Such amines include compounds of the formula ##STR1## in which R.sub.1 is alkyl of 8 to 20 carbon atoms and each R.sub.2 is hydrogen or alkyl of 1 t
4740504 Antihyperlipidemic amine boranes April 26, 1988
Trialkylamine borane compounds are useful as antihyperlipidemic agents for lowering serum cholesterol and triglyceride levels in mammals.
4689328 Process for controlling hyperlipidemia August 25, 1987
A process for controlling hyperlipidemia in mammals is disclosed. In this process a mammal suffering from hyperlipidemia is treated with a hyperlipidemia controlling effective amount of a compound having the structural formula ##STR1## wherein R.sup.1 is mercapto, amino, hydroxy
4689326 Process for controlling hyperlipidemia August 25, 1987
A process for controlling hyperlipidemia in mammals is disclosed. In this process a hyperlipidemia controlling effective amount of a compound having structural formula: ##STR1## where R.sup.1 is hydrogen, oxo, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl; R.sup.2 is hydrog
4672060 Antihyperlipidemic ammonium polyboranes June 9, 1987
Ammonium salts of polyboranes are useful as antihyperlipidemic agents for lowering serum cholesterol and triglyceride levels in mammals. Such polyborane ions include the B.sub.3 H.sub.8.sup.- and B.sub.n H.sub.n.sup.= groups in which n is 6 to 12.
4647555 Esters of boron analogues of amino acids March 3, 1987
Ester analogues of boron analogues of amino acid are disclosed. Also disced is a method of forming the ester analogues in high yield by condensation of the corresponding acids and alcohols with dicylohexylcarbodiimide at room temperature in dichloromethane. The disclosed compounds h
4587359 Amine-carbamoylborane adducts May 6, 1986
This invention involves amine-carbamoylborane compounds of the formulawherein R.sub.1 and R.sub.2 are hydrogen or certain alkyl moieties and R..3 is an alkyl. A process for their preparation involving an amine displacement reaction is also described. A method of use and pharmaceutical c
4550186 Binuclear copper (II) carboxylates formed from amine-carboxyboranes October 29, 1985
A compound of the formulawherein each R independently represents H, C.sub.1 -C.sub.10 alkyl, or phenyl and L represents a non-toxic Lewis base capable of forming a coordinate bond with the copper with the provisos that any two or three R attached to the same nitrogen may represent a C.su
4499303 Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides February 12, 1985
This invention relates to novel N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides and pharmacologically acceptable salts thereof, a method for lowering serum levels in mammals by administration of said compounds, and pharmaceutical compositions thereof.
4368194 Pharmacologically active amine boranes January 11, 1983
The use of a mine boranes to inhibit the inflammation process is disclosed. hese boranes, which are boron analogs of .alpha.-amino acids, effectively block the following: general inflammation, induced arthritis, and the writhing reflex associated with inflammation pain. The inflammation
4312989 Pharmacologically active amine boranes January 26, 1982
The use of amine boranes to inhibit the inflammation process is disclosed. These boranes, which are boron analogs of .alpha.-amino acids, effectively block the following: general inflammation, induced arthritis, and the writhing reflex associated with inflammation pain. The inflammation
4209510 Ammonia-cyanoborane, sodium iodide complex June 24, 1980
Preparation of the crystalline complex [Na{NH.sub.3.BH.sub.2 -(CN)}.sub.6 from NMe.sub.3.BH.sub.2 I and NaCN in liquid NH.sub.3 is disclosed. Structural details of this novel octahedral complex are obtained by single-crystal X-ray analysis. Evidence indicates that the complex is a v










 
 
  Recently Added Patents
Portable reading device with mode processing
Soft co-processors to provide a software service function off-load architecture in a multi-core processing environment
Image processing apparatus and image processing method
Expandable mobile device
LED package with top and bottom electrodes
Stable file system
Assigning runtime artifacts to software components
  Randomly Featured Patents
Method for connection establishment in a radio system relaying packet-switched traffic
Apparatus and method for efficient TDMA bandwidth allocation for TCP/IP satellite-based networks
Method and apparatus for decoding/encoding a video signal
Hydrocarbon conversion using nanocrystalline zeolite Y
Microcellular foams containing an infrared attenuating agent and a method of using
Board game apparatus
Transceiver with controller for authentication
Manufacture of linear primary aldehydes and alcohols
Illuminating system
Dual in-line packaging and method of producing the same